Article
Oncology
Sea R. Choi, Chae Young Hwang, Jonghoon Lee, Kwang-Hyun Cho
Summary: In this study, a simplified but essential molecular regulatory network model was constructed through transcriptomic analysis, and inhibition of BCL11A was identified as a potential target for reprogramming basal-like cancer cells into luminal A cells.
Review
Oncology
Amaia Arruabarrena-Aristorena, Eneda Toska
Summary: The majority of breast cancers are ER+, and agents targeting the ER signaling pathway have significantly improved survival for patients. However, therapeutic resistance is a challenge, particularly in metastatic cases. In recent years, disrupted epigenetic regulatory processes have been identified as major contributors to cancer development, including breast cancer. Aberrations in chromatin modifiers and transcription factors have also been associated with breast cancer development and treatment outcomes, leading to the proposal of new epigenetic-based therapies in combination with targeted treatments to overcome resistance.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Roser Zaurin, Roberto Ferrari, Ana Silvina Nacht, Jose Carbonell, Francois Le Dily, Jofre Font-Mateu, Lara Isabel de Llobet Cucalon, Enrique Vidal, Antonios Lioutas, Miguel Beato, Guillermo P. Vicent
Summary: In T47D breast cancer cells, 50 pM progestin can activate cell cycle entry and the progesterone gene expression program. Highly accessible sites (HAs) are enriched in RAD21 and CTCF, but PR binding is the driving force for the most robust interactions with hormone-regulated genes, indicating their potential usefulness as targets for therapeutic intervention.
NUCLEIC ACIDS RESEARCH
(2021)
Review
Chemistry, Medicinal
Teesha Downton, Fiona Zhou, Davendra Segara, Rinath Jeselsohn, Elgene Lim
Summary: The translated article discusses the limitations of current endocrine therapies for ER-positive breast cancer and the mechanisms of drug resistance, focusing on ESR1 mutations. It also provides an overview of the development and research progress of oral SERDs in improving treatment outcomes.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Biochemistry & Molecular Biology
Ying Liang, Qi Lu, Wei Li, Dapeng Zhang, Fanglin Zhang, Qingping Zou, Lu Chen, Ying Tong, Mengxing Liu, Shaoxuan Wang, Wenxuan Li, Xiaoguang Ren, Peng Xu, Zhicong Yang, Shihua Dong, Baolong Zhang, Yanni Huang, Daqiang Li, Hailin Wang, Wenqiang Yu
Summary: Dysfunction of Tumour Suppressor Genes (TSGs) is common in carcinogenesis, with low expression of miRNA potentially reducing TSG activity through enhancer regulation. In breast cancer, downregulation of GPER1 and miR-339 is observed, with mechanistic investigations revealing the role of miR-339 in upregulating GPER1 expression through enhancer switching. This highlights a potential alternative strategy for breast cancer treatment through reactivation of TSGs by enhancer manipulation.
NUCLEIC ACIDS RESEARCH
(2021)
Article
Multidisciplinary Sciences
Pauliina M. Munne, Lahja Martikainen, Iiris Raty, Kia Bertula, Nonappa, Janika Ruuska, Hanna Ala-Hongisto, Aino Peura, Babette Hollmann, Lilya Euro, Kerim Yavuz, Linda Patrikainen, Maria Salmela, Juho Pokki, Mikko Kivento, Juho Vaananen, Tomi Suomi, Liina Nevalaita, Minna Mutka, Panu Kovanen, Marjut Leidenius, Tuomo Meretoja, Katja Hukkinen, Outi Monni, Jeroen Pouwels, Biswajyoti Sahu, Johanna Mattson, Heikki Joensuu, Paivi Heikkila, Laura L. Elo, Ciara Metcalfe, Melissa R. Junttila, Olli Ikkala, Juha Klefstrom
Summary: Researchers found that matrix stiffness regulates ERα expression via stress-mediated p38 activation and H3K27me3-mediated epigenetic regulation, revealing a crucial mechanobiological component in hormonal signaling in breast tissue.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Emily Smart, Svetlana E. Semina, Luis H. Alejo, Nidhi S. Kansara, Jonna Frasor
Summary: This study identifies two specific gene signatures in estrogen receptor (ER)-positive breast cancer that are associated with invasion and poor patient outcome. The findings reveal the complex role of ER in promoting invasion and metastasis and provide insights into potential targeted therapies.
Article
Oncology
Fei Fei, Gene P. Siegal, Shi Wei
Summary: The study analyzed clinicopathologic features and clinical outcomes of ER-low-positive breast cancers. ER-low-positive tumors showed significantly better prognosis compared to ER-negative tumors, with overlapping survival outcomes with ER-positive tumors in the entire cohort.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Endocrinology & Metabolism
Shuying Hu, Feiying Yin, Litao Nie, Yuqin Wang, Jian Qin, Jian Chen
Summary: This study discusses the impact of coronavirus infection on breast cancer patients and the potential therapeutic strategy of selective estrogen receptor modulators (SERMs).
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice Andre, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai
Summary: This study compared the response to neoadjuvant chemotherapy and survival between patients with triple-negative breast cancer (TNBC) and non-TNBC. The results showed that TNBC patients had higher pathologic complete response rates but lower 3-year progression-free survival rates and 3-year overall survival rates. TNBC was associated with increased risk for visceral metastases, lower risk for bone recurrence, and shorter postrecurrence survival. Patients with TNBC had worse survival if they had residual disease after neoadjuvant chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Iva Busic-Pavlek, Ivo Dumic-Cule, Lucija Kovacevic, Milan Milosevic, Petra Delimar, Lea Korsa, Zlatko Marusic, Maja Prutki
Summary: The calcium-sensing receptor (CaSR) is important in maintaining calcium balance and altered signaling through CaSR is associated with the development of various tumors including colorectal and breast tumors. A retrospective study involving 79 patients with invasive breast carcinoma explored the expression of CaSR in breast cancer. The study found that higher CaSR expression was correlated with larger tumor size, presence of HER2 receptors, lymph node involvement, distant metastasis, and increased Ki-67 proliferation index. This suggests that higher CaSR expression may indicate a poor prognosis and treatment outcome in breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Jiaqi Yao, Yiran Tao, Zelin Hu, Junjie Li, Ziyi Xue, Ya Zhang, Yi Lei
Summary: This paper provides a comprehensive review of ER's structural functions and highlights the recent advancements in novel drugs targeting ER, namely SERD and SERCA, focusing on their structural optimization strategies and future directions. It also discusses the therapeutic potential and challenges of these drugs in breast cancer and other ER-related diseases.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Seng Chuan Tang, Quentin Lion, Olivier Peulen, Philippe Chariot, Arnaud Lavergne, Alice Mayer, Paula Allepuz Fuster, Pierre Close, Sebastian Klein, Alexandra Florin, Reinhard Buettner, Ivan Nemazanyy, Kateryna Shostak, Alain Chariot
Summary: COP1 acts as an oncogenic E3 ligase by promoting ERα signaling but also acts as a tumor suppressor candidate by preventing EMT, reflecting a dual role of COP1 in breast cancer that has sparked widespread interest in the academic community.
Review
Oncology
Naoko Honma, Yoko Matsuda, Tetuo Mikami
Summary: TNBC lacks an effective treatment target and is usually associated with a poor clinical outcome due to hormone unresponsiveness. Besides ER-alpha, other sex steroid receptors like AR, ER-beta, and GPER are frequently expressed in TNBC, highlighting the importance of understanding their biological and clinical significance in TNBC. A comprehensive viewpoint on the role of sex steroid hormones in TNBC is crucial for correctly understanding the association between the carcinogenic mechanism or pathobiology of TNBC and sex steroid hormones.
Article
Oncology
D. Gareth Evans, Kelly-Anne Phillips, Roger L. Milne, Robert Fruscio, Cezary Cybulski, Jacek Gronwald, Jan Lubinski, Tomasz Huzarski, Zerin Hyder, Claire Forde, Kelly Metcalfe, Leigha Senter, Jeffrey Weitzel, Nadine Tung, Dana Zakalik, Maria Ekholm, Ping Sun, Steven A. Narod
Summary: This study aimed to estimate the impact of different treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation. The results indicated that bilateral oophorectomy was associated with a reduced risk of death from breast cancer.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Csilla Olah, Henning Reis, Michele J. Hoffmann, Fabian Mairinger, Saskia Ting, Boris Hadaschik, Ulrich Krafft, Viktor Gruenwald, Peter Nyirady, Melinda Varadi, Balazs Gyorffy, Andras Kiss, Eszter Szekely, Gottfrid Sjodahl, Tibor Szarvas
Summary: The study proposed a method for molecular classification of bladder cancer samples, and evaluated the impact of subtypes on survival after adjuvant chemotherapy. The results showed that luminal subtypes had better survival with chemotherapy, while basal subtypes did not show significant differences. High APOBEC3G expression was associated with better survival in platinum-treated patients. The proposed method is reliable for classifying tissue samples and subtypes have a significant impact on adjuvant chemotherapy.
Review
Multidisciplinary Sciences
Balazs Gyorffy, Boglarka Weltz, Istvan Szabo
Summary: A grant decision support tool was established in Hungary to rank the scientific productivity of researchers. The introduction of this tool increased the correlation between grant selection and scientometric parameters, leading to enhanced transparency in the review process.
Article
Oncology
Melinda Varadi, Nikolett Nagy, Henning Reis, Boris Hadaschik, Christian Niedworok, Orsolya Modos, Attila Szendroi, Jason Ablat, Peter C. Black, David Keresztes, Anita Csizmarik, Csilla Olah, Nadine T. Gaisa, Andras Kiss, Jozsef Timar, Erika Toth, Erzsebet Csernak, Arpad Gerstner, Vinay Mittal, Sofia Karkampouna, Marianna Kruithof de Julio, Balazs Gyorffy, Gabor Bedics, Michael Rink, Margit Fisch, Peter Nyirady, Tibor Szarvas
Summary: In this study, a data-processing pipeline was developed for the detection and interpretation of genetic alterations in two rare cancers. The analysis revealed a high rate of actionable mutations, suggesting potential feasibility for the treatment of urachal adenocarcinoma and primary bladder adenocarcinoma.
Article
Oncology
N. Woldmar, A. Schwendenwein, M. Kuras, B. Szeitz, K. Boettiger, A. Tisza, V Laszlo, L. Reiniger, A. G. Bago, Z. Szallasi, J. Moldvay, A. M. Szasz, J. Malm, P. Horvatovich, L. Pizzatti, G. B. Domont, F. Renyi-Vamos, K. Hoetzenecker, M. A. Hoda, G. Marko-Varga, K. Schelch, Z. Megyesfalvi, M. Rezeli, B. Dome
Summary: This study investigated the proteomic differences between primary lung adenocarcinoma (LADC) and corresponding brain metastases. The results revealed differential expression of proteins related to the immune system, cell-cell interactions, migration, metabolism, translation, and vesicle formation. Additionally, differences were observed in the proteomic profiles of fast-progressing patients compared to slow-progressing individuals. The findings provide insights into the biology of LADC brain metastases and may contribute to the development of personalized follow-up strategies.
Article
Chemistry, Multidisciplinary
Szonja Anna Kovacs, Janos Tibor Fekete, Balazs Gyorffy
Summary: Immune-checkpoint inhibitors have shown promising effects in the treatment of various tumor types. This study established a database and web platform to identify biomarkers of response to immunotherapy and facilitate further analysis and validation of new biomarker candidates.
ACTA PHARMACOLOGICA SINICA
(2023)
Article
Oncology
Zsuzsanna Valko, Zsolt Megyesfalvi, Anna Schwendenwein, Christian Lang, Sandor Paku, Nandor Barany, Bence Ferencz, Anita Horvath-Rozsas, Ildiko Kovacs, Erzsebet Schlegl, Veronika Pozonec, Kristiina Boettiger, Melinda Rezeli, Gyorgy Marko-Varga, Ferenc Renyi-Vamos, Mir Alireza Hoda, Thomas Klikovits, Konrad Hoetzenecker, Michael Grusch, Viktoria Laszlo, Balazs Dome, Karin Schelch
Summary: This study demonstrates the subtype specificity of BCL-2 expression and reveals the mechanism of venetoclax resistance in SCLC. Moreover, it provides preclinical evidence that combined BCL-2 and MCL-1 targeting is an effective approach to overcome venetoclax resistance in high BCL-2-expressing SCLCs with intact BAX.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Jozsef Timar, Kenneth V. Honn, Mary J. C. Hendrix, Gyorgy Marko-Varga, Sirpa Jalkanen
Summary: Cancer plasticity, characterized by disturbances of cell differentiation programs, is a recognized hallmark of cancer. It includes various forms such as epithelial-mesenchymal transition (EMT), vasculogenic mimicry, and megakaryocytic mimicry. Immunogenic mimicry (IGM), a type of cancer plasticity, involves the expression of immune cell genes regulated by interferons (IFNs), often due to gene amplifications. These IGM genes play a role in immune escape of cancers and offer potential targets for immunotherapeutics.
CANCER AND METASTASIS REVIEWS
(2023)
Article
Obstetrics & Gynecology
J. Cadenas, L. C. Poulsen, D. Nikiforov, M. L. Grondahl, A. Kumar, K. Bahnu, A. L. M. Englund, J. Malm, G. Marko-Varga, I Pla, A. Sanchez, S. E. Pors, C. Yding Andersen
Summary: This study investigates the substances and signal transduction pathways involved in the regulation of human oocyte maturation downstream to the effects of FSH and LH. The results reveal that human oocyte maturation is a multifactorial process involving several different signal transduction pathways. Various pathways, including those involving CNP, EGF-related peptides, TGF-beta family members, activins/inhibins, FF-MAS, and MDK, are potentially active, while the GDF9 and BMP15 pathways show less pronounced influence.
HUMAN REPRODUCTION
(2023)
Article
Virology
Elena K. Kokinos, Sergey A. Tsymbal, Anastasia V. Galochkina, Svetlana A. Bezlepkina, Julia V. Nikolaeva, Sofia O. Vershinina, Anna A. Shtro, Victor V. Tatarskiy, Alexander A. Shtil, Eugenia V. Broude, Igor B. Roninson, Marina Dukhinova
Summary: Hyperactivation of the immune system is a life-threatening complication in viral and bacterial infections, especially pneumonia. This study found that a selective CDK8/19 inhibitor, Senexin B, could suppress the inflammatory response of monocytic cells to H1N1 influenza virus and bacterial lipopolysaccharides, reducing inflammation symptoms.
Article
Oncology
Lucia Paniagua-Herranz, Bernard Doger, Cristina Diaz-Tejeiro, Adrian Sanvicente, Cristina Nieto-Jimenez, Victor Moreno, Pedro Perez Segura, Balazs Gyorffy, Emiliano Calvo, Alberto Ocana
Summary: This study explored the high expression of EGFR and MET in prostate adenocarcinoma and pancreatic adenocarcinoma, and found that it was related to high expression of PD-L1, suggesting the potential for future combination therapy using bi-specific EGFR/MET antibodies and anti-PD(L)1 inhibitors.
Article
Oncology
Darya Chetverina, Nadezhda E. Vorobyeva, Balazs Gyorffy, Alexander A. Shtil, Maksim Erokhin
Summary: The study identified crucial genes (known as Supertargets) for tumors of specific tissue origin, which can be targeted for personalized treatment strategies. Most of the Supertargets were DNA-binding transcription factors, suggesting the importance of transcriptional mechanisms in cell survival of specific tumors. Targeted inactivation of these factors provides a straightforward approach to optimize therapeutic regimens.
Article
Geriatrics & Gerontology
Balazs Gyorffy
Summary: Progress in the treatment of ovarian cancer is behind other tumor types. A large-scale transcriptomic database was established to identify survival-associated genes. The database includes 1816 samples, with 2468 genes correlated to progression-free survival (PFS) and 704 genes correlated with overall survival (OS).
Article
Pharmacology & Pharmacy
Balazs Gyorffy
Summary: This study established a comprehensive database of transcriptome-level data for lung cancer, which can be used to identify and rank the most promising biomarkers and therapeutic targets for different subtypes of lung cancer.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Cinzia Giordano, Felice Maria Accattatis, Luca Gelsomino, Piercarlo Del Console, Balazs Gyorffy, Mario Giuliano, Bianca Maria Veneziani, Grazia Arpino, Carmine De Angelis, Pietro De Placido, Erica Pietroluongo, Francesco Zinno, Daniela Bonofiglio, Sebastiano Ando, Ines Barone, Stefania Catalano
Summary: This study identified novel miRNA signatures, miRNA-27a and miRNA-128, in breast cancer by analyzing the expression profiles of EV-derived miRNAs in the blood circulation. These miRNAs showed diagnostic accuracy in distinguishing breast cancer patients from non-cancer controls.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Esther Cabanas Morafraile, Cristina Saiz-Ladera, Cristina Nieto-Jimenez, Balazs Gyorffy, Adam Nagy, Guillermo Velasco, Pedro Perez-Segura, Alberto Ocana
Summary: This study describes a novel therapeutic strategy for treating colorectal cancer (CRC) patients with BRAF mutations. By identifying upregulated proteins on the surface of tumor cells as treatment targets and observing the transcriptional profile associated with antigen presenting cells, it is suggested that a combination of anti PD(L)1 with other co-inhibitor receptors can be explored for treating BRAF-mutated CRC patients.